June 1, 2017
MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries
PORTLAND, OR and CAMBRIDGE, MA— June 1, 2017 — MolecularMD Corp., a molecular diagnostics company that provides clinical trial services and development of companion diagnostics for targeted and immunotherapies in oncology, is now recognized as a Certified Service Provider of ArcherDX next-generation sequencing (NGS) panels, adding to MolecularMD’s NGS Advanced Diagnostics service offering. The agreement solidifies MolecularMD as a technically proficient service provider of NGS-based solutions for clinical research that support precision medicine.
MolecularMD will leverage their Cambridge, Massachusetts-based CLIA laboratory and Advanced Diagnostic Business Unit to provide biopharma clients with the capability to interrogate nucleic acids for fusions, copy number variations (CNVs) and single nucleotide variants (SNVs) as well as to perform expression and immune-profiling. Cindy Spittle, V.P. of Development and Scientific Affairs at MolecularMD, stated, “ArcherDX’s approach to NGS chemistries has helped us to address some of the unmet needs in genomic sequencing. Our clients rely on us to deliver content with a high level of accuracy and precision. The CSP designation from ArcherDX is a further endorsement to our company’s quality philosophy.”